BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66. [PMID: 9989342 DOI: 10.2165/00003088-199936010-00004] [Cited by in Crossref: 170] [Cited by in F6Publishing: 167] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Tarinas A, Tápanes R, Ferrer G, Pérez J. Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. Farmacia Hospitalaria 2007;31:243-7. [DOI: 10.1016/s1130-6343(07)75381-3] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
2 Fekadu S, Alemayehu E, Dewil R, Van der Bruggen B. Electrochemical degradation of antivirus drug lamivudine formulation: photoelectrocoagulation, peroxi-electrocoagulation, and peroxi-photoelectrocoagulation processes. J Appl Electrochem 2021;51:607-18. [DOI: 10.1007/s10800-020-01521-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Patel JR, Barve KH. Intestinal permeability of Lamivudine using single pass intestinal perfusion. Indian J Pharm Sci 2012;74:478-81. [PMID: 23716881 DOI: 10.4103/0250-474X.108441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chantry CJ, Morrison P, Panchula J, Rivera C, Hillyer G, Zorilla C, Diaz C. Effects of Lipolysis or Heat Treatment on HIV-1 Provirus in Breast Milk: . Journal of Acquired Immune Deficiency Syndromes 2000;24:325-9. [DOI: 10.1097/00042560-200008010-00005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16:551-60. [PMID: 11872998 DOI: 10.1097/00002030-200203080-00006] [Cited by in Crossref: 107] [Cited by in F6Publishing: 92] [Article Influence: 5.4] [Reference Citation Analysis]
6 Chen L, Al-Harthi L, Hu XT. Triumeq Increases Excitability of Pyramidal Neurons in the Medial Prefrontal Cortex by Facilitating Voltage-Gated Ca2+ Channel Function. Front Pharmacol 2020;11:617149. [PMID: 33584297 DOI: 10.3389/fphar.2020.617149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Littler E, Zhou X. Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus. Comprehensive Medicinal Chemistry II. Elsevier; 2007. pp. 295-327. [DOI: 10.1016/b0-08-045044-x/00212-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio DZ. Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother 2006;50:2686-94. [PMID: 16870759 DOI: 10.1128/AAC.01637-05] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
9 Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother 2007;51:4297-302. [PMID: 17893155 DOI: 10.1128/AAC.00332-07] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mosconi G, Scolari M, Manna C, Canova C, Cristino S, Campieri C, Liviano D’arcangelo G, Morelli C, Faenza A, Stefoni S. Lamivudine in recurrent hepatitis B after renal transplantation. Transplantation Proceedings 2001;33:1873-4. [DOI: 10.1016/s0041-1345(00)02731-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis. 2001;1:232-241. [PMID: 11871510 DOI: 10.1016/s1473-3099(01)00118-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
12 Choi CI, Bae JW, Keum SK, Lee YJ, Lee HI, Jang CG, Lee SY. Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine. Xenobiotica 2013;43:636-40. [PMID: 23252721 DOI: 10.3109/00498254.2012.747710] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Minzi O, Mugoyela V, Gustafsson L. Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients. Ther Clin Risk Manag 2011;7:441-6. [PMID: 22162920 DOI: 10.2147/TCRM.S23625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Sokal EM, Roberts EA, Mieli-Vergani G, McPhillips P, Johnson M, Barber J, Dallow N, Boxall E, Kelly D. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother. 2000;44:590-597. [PMID: 10681323 DOI: 10.1128/aac.44.3.590-597.2000] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
15 Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215-1221. [PMID: 21703206 DOI: 10.1016/j.jhep.2011.02.032] [Cited by in Crossref: 256] [Cited by in F6Publishing: 222] [Article Influence: 23.3] [Reference Citation Analysis]
16 Janssen EJH, Bastiaans DET, Välitalo PAJ, van Rossum AMC, Jacqz-Aigrain E, Lyall H, Knibbe CAJ, Burger DM. Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. Br J Clin Pharmacol 2017;83:1287-97. [PMID: 28079918 DOI: 10.1111/bcp.13227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
17 DeJesus E, Saleh S, Cheng S, van der Mey D, Becker C, Frey R, Unger S, Mueck W. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. Pulm Circ 2019;9:2045894019848644. [PMID: 30997864 DOI: 10.1177/2045894019848644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 De Sousa Mendes M, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, Blanche S, Treluyer JM, Benaboud S. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol 2015;80:1031-41. [PMID: 26011128 DOI: 10.1111/bcp.12685] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
19 Bollen P, Reiss P, Schapiro J, Burger D. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf 2015;14:1457-72. [PMID: 26134478 DOI: 10.1517/14740338.2015.1059818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
20 Akanbi MO, Scarsi KK, Taiwo B, Murphy RL. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother 2012;13:65-79. [PMID: 22149368 DOI: 10.1517/14656566.2012.642865] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
21 Flynn PM, Rodman J, Lindsey JC, Robbins B, Capparelli E, Knapp KM, Rodriguez JF, McNamara J, Serchuck L, Heckman B, Martinez J; PACTG P1012 Team. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother 2007;51:3516-22. [PMID: 17664328 DOI: 10.1128/AAC.01626-06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wakui Y, Inoue J, Ueno Y, Fukushima K, Kondo Y, Kakazu E, Obara N, Kimura O, Shimosegawa T. Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-γ ligand, rosiglitazone. Biochemical and Biophysical Research Communications 2010;396:508-14. [DOI: 10.1016/j.bbrc.2010.04.128] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
23 Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. Seminars in Fetal and Neonatal Medicine 2005;10:161-75. [DOI: 10.1016/j.siny.2004.10.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
24 Dumitrescu TP, Peddiraju K, Fu C, Bakshi K, Yu S, Zhang Z, Tenorio AR, Spancake C, Joshi S, Wolstenholme A, Adkison K. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine. Clin Pharmacol Drug Dev 2020;9:189-202. [PMID: 31724343 DOI: 10.1002/cpdd.740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Li X, Liu B, Sun Y, Chen H, Chen H, Zhang H, Zhang Q, Ding Y. Single-dose pharmacokinetic properties, bioavailability, and tolerability of two lamivudine 100-mg tablet formulations: a randomized crossover study in healthy Chinese male subjects. Clin Ther 2013;35:1546-56. [PMID: 24011635 DOI: 10.1016/j.clinthera.2013.07.431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Akhtar R, Yousaf M, Zahoor AF, Naqvi SAR, Abbas N. Synthesis of lamivudine (3TC) and its derivatives. Phosphorus, Sulfur, and Silicon and the Related Elements 2017;192:989-1001. [DOI: 10.1080/10426507.2017.1321648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
27 Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherborne B, Cooper I, Platts JA. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. Journal of Pharmaceutical Sciences 2001;90:749-84. [DOI: 10.1002/jps.1031] [Cited by in Crossref: 333] [Cited by in F6Publishing: 287] [Article Influence: 15.9] [Reference Citation Analysis]
28 Narang VS, Lulla A, Malhotra G, Purandare S. A Combined-Formulation Tablet of Lamivudine/Nevirapine/Stavudine: Bioequivalence Compared With Concurrent Administration of Lamivudine, Nevirapine, and Stavudine in Healthy Indian Subjects. The Journal of Clinical Pharmacology 2005;45:265-74. [DOI: 10.1177/0091270004273343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
29 Haché C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother. 2006;7:1835-1843. [PMID: 16925509 DOI: 10.1517/14656566.7.13.1835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
30 Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002;46:2525-2532. [PMID: 12121928 DOI: 10.1128/aac.46.8.2525-2532.2002] [Cited by in Crossref: 148] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
31 Li Q, Ye Z, Zhu P, Guo D, Yang H, Huang J, Zhang W, Polli JE, Shu Y. Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1). Pharm Res 2018;35:14. [PMID: 29302757 DOI: 10.1007/s11095-017-2290-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
32 Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? Antimicrob Agents Chemother 2010;54:3280-6. [PMID: 20516271 DOI: 10.1128/AAC.00306-10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS 2017;31 Suppl 2:S173-84. [PMID: 28471948 DOI: 10.1097/QAD.0000000000001401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
34 Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, Fletcher CV, Fiscus S, Raffanti S, Donlon R, McKinsey J, Nicotera J, Schmidt D, Shoup RE, Kates RE, Lloyd RM Jr, Larder B. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses 2000;16:1491-502. [PMID: 11054262 DOI: 10.1089/088922200750006010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.5] [Reference Citation Analysis]
35 Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther 2012;91:272-80. [PMID: 22190066 DOI: 10.1038/clpt.2011.225] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
36 Qi D, Yi JH, Shen GY. Antiviral therapy of chronic hepatitis B in women of childbearing age. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1634-1638 [DOI: 10.11569/wcjd.v19.i15.1634] [Reference Citation Analysis]
37 Navér L, Albert J, Carlander C, Flamholc L, Gisslén M, Karlström O, Svedhem-Johansson V, Sönnerborg A, Westling K, Yilmaz A, Pettersson K. Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017. Infect Dis (Lond) 2018;50:495-506. [PMID: 29363407 DOI: 10.1080/23744235.2018.1428825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
38 Nakamuta M, Morizono S, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Furusyo N, Nomura H, Sakai H, Takahashi K, Azuma K, Shimoda S, Kotoh K, Enjoji M, Hayashi J; Kyushu University Liver Disease Study Group. Relationship between body surface area and ALT normalization after long-term lamivudine treatment. World J Gastroenterol 2005;11:6948-53. [PMID: 16437598 DOI: 10.3748/wjg.v11.i44.6948] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
39 Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, Hoelscher DD. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004;48:176-82. [PMID: 14693537 DOI: 10.1128/AAC.48.1.176-182.2004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
40 Singh RP, Adkison K, Wolstenholme A, Hopking J, Wynne B. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clin Pharmacol Drug Dev 2021;10:985-93. [PMID: 34265164 DOI: 10.1002/cpdd.996] [Reference Citation Analysis]
41 Chantry CJ, Morrison P, Panchula J, Rivera C, Hillyer G, Zorilla C, Diaz C. Effects of lipolysis or heat treatment on HIV-1 provirus in breast milk. J Acquir Immune Defic Syndr 2000;24:325-9. [PMID: 11015148 DOI: 10.1097/00126334-200008010-00005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
42 Kim HS, Sunwoo YE, Ryu JY, Kang HJ, Jung HE, Song IS, Kim EY, Shim JC, Shon JH, Shin JG. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 2007;64:645-54. [PMID: 17509035 DOI: 10.1111/j.1365-2125.2007.02944.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
43 Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol 2003; 9(7): 1501-1503 [PMID: 12854150 DOI: 10.3748/wjg.v9.i7.1501] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
44 Alebouyeh M, Amini H. Rapid determination of lamivudine in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2015;975:40-4. [PMID: 25438241 DOI: 10.1016/j.jchromb.2014.11.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
45 Keay S, Oldach D, Redfield R, Bartlett S. Organ transplantation in the HIV-infected patient: . Current Opinion in Organ Transplantation 2000;5:217-23. [DOI: 10.1097/00075200-200009000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
46 Burger DM, Verweel G, Rakhmanina N, Verwey-Van Wissen CP, La Porte CJ, Bergshoeff AS, Lyall H, Hartwig NG, Green H, Soldin S, Gibb DM, de Groot R. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007;81:517-20. [PMID: 17329994 DOI: 10.1038/sj.clpt.6100118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
47 Torre F, Mattioli F, Campo N, Delfino A, Basso M, Pelli N, Martelli A, Picciotto A. Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant. Dig Liver Dis 2004;36:677-81. [PMID: 15506667 DOI: 10.1016/j.dld.2004.03.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Yao GB. Management of hepatitis B in China. J Med Virol 2000;61:392-7. [DOI: 10.1002/1096-9071(200007)61:3<392::aid-jmv19>3.0.co;2-v] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
49 Casado JL, Bañón S. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection. Expert Rev Clin Pharmacol 2015;8:709-18. [PMID: 26517111 DOI: 10.1586/17512433.2015.1090873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 Aye IL, Singh AT, Keelan JA. Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. Chem Biol Interact. 2009;180:327-339. [PMID: 19426719 DOI: 10.1016/j.cbi.2009.04.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
51 Liu MH, Sheng YJ, Liu JY, Hu HD, Zhang QF, Ren H. Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med 2013;33:169-76. [PMID: 23563007 DOI: 10.5144/0256-4947.2013.169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
52 Cattaneo D, Capetti A, Rizzardini G. Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opin Drug Metab Toxicol 2019;15:245-52. [PMID: 30704313 DOI: 10.1080/17425255.2019.1577821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Loutfy MR, Ackad N, Antoniou T, Baril J, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS. Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen. HIV Clinical Trials 2015;8:259-68. [DOI: 10.1310/hct0805-259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Ma L, Alla NR, Li X, Mynbaev OA, Shi Z. Mother-to-child transmission of HBV: review of current clinical management and prevention strategies: Mother-to-child transmission of HBV. Rev Med Virol 2014;24:396-406. [DOI: 10.1002/rmv.1801] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
55 Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-278. [PMID: 15296954 DOI: 10.1016/j.ejpb.2004.03.001] [Cited by in Crossref: 478] [Cited by in F6Publishing: 405] [Article Influence: 28.1] [Reference Citation Analysis]
56 Kumar A, Dwivedi M, Misra SP, Narang S, Tiwari BK, Pandey R. Clinical profile, genotype and management updates of hepatitis B virus. Indian J Virol 2011;22:1-10. [PMID: 23637496 DOI: 10.1007/s13337-011-0037-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011;12:905-12. [PMID: 21570912 DOI: 10.1016/S1470-2045(11)70056-0] [Cited by in Crossref: 92] [Cited by in F6Publishing: 38] [Article Influence: 8.4] [Reference Citation Analysis]
58 Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Tréluyer JM, Urien S. Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob Agents Chemother 2011;55:3498-504. [PMID: 21576443 DOI: 10.1128/AAC.01622-10] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
59 Alnouti Y, Lewis SR, White CA, Bartlett MG. Simultaneous determination of zidovudine and lamivudine from rat tissues by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:503-8. [DOI: 10.1002/rcm.1816] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
60 Shah K, Fischetti B, Cha A, Taft DR. Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine. CDDT 2020;17:387-96. [DOI: 10.2174/1570163816666190214164916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Strauch S, Jantratid E, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: lamivudine. J Pharm Sci 2011;100:2054-63. [PMID: 21491435 DOI: 10.1002/jps.22449] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
62 Choi MK, Song IS. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos 2012;33:170-8. [PMID: 22415520 DOI: 10.1002/bdd.1783] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
63 Enioutina EY, Constance JE, Stockmann C, Linakis MW, Yu T, Rower JE, Balch AH, Sherwin CM. Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opin Drug Metab Toxicol 2015;11:1861-78. [PMID: 26535960 DOI: 10.1517/17425255.2015.1108963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
64 Tomasiewicz K, Modrzewska R, Krawczuk G, Lyczak A. Lamivudine therapy for chronic hepatitis B virus infection and pregnancy: a case report. Int J Infect Dis. 2001;5:115-116. [PMID: 11468109 DOI: 10.1016/S1201-9712(01)90038-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
65 Damle BD, Kaul S, Behr D, Knupp C. Bioequivalence of Two Formulations of Didanosine, Encapsulated Enteric-Coated Beads and Buffered Tablet, in Healthy Volunteers and HIV-Infected Subjects. The Journal of Clinical Pharmacology 2002;42:791-7. [DOI: 10.1177/009127002401102623] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
66 Dusheiko G. Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis? Lancet. 2012;379:2019-2021. [PMID: 22549045 DOI: 10.1016/s0140-6736(11)61182-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
67 Petrova M, Kamburov V. Breastfeeding and chronic HBV infection: Clinical and social implications. World J Gastroenterol 2010; 16(40): 5042-5046 [PMID: 20976840 DOI: 10.3748/wjg.v16.i40.5042] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
68 Yan JH, Bifano M, Olsen S, Smith RA, Zhang D, Grasela DM, LaCreta F. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J ClinPharmacol. 2006;46:1250-1258. [PMID: 17050790 DOI: 10.1177/0091270006293304] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
69 Kalayci AG, Dagdemir A, Dilber C, Albayrak D. Evans syndrome related to hepatitis B virus infection: a case that responded only to lamivudine therapy. J Pediatr Gastroenterol Nutr 2001;32:493-5. [PMID: 11396822 DOI: 10.1097/00005176-200104000-00021] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
70 Chtioui H, Millius C, Lämmle B, Lauterburg BH. Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. British Journal of Haematology 2009;144:136-7. [DOI: 10.1111/j.1365-2141.2008.07432.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
71 Li Z, Shang L, Liu C, Ma P, Wu C, Zhang W, Sun Y, Wang Y, Liu X, Sun J. Evaluation of pharmacokinetics underlies the collaborated usage of lamivudine and oxymatrine in beagle dogs. Asian Journal of Pharmaceutical Sciences 2016;11:641-7. [DOI: 10.1016/j.ajps.2016.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J, Pastor-Anglada M. Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Front Pharmacol 2016;7:175. [PMID: 27445813 DOI: 10.3389/fphar.2016.00175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
73 Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Lewis SM, Lee FW, Aidoo A, Leakey JE, Dunnick JK, Heflich RH. Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC. Environ Mol Mutagen 2007;48:270-82. [DOI: 10.1002/em.20280] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
74 Benaboud S, Tréluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, Rey E, Pannier E, Firtion G, Launay O, Hirt D. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother 2012;56:776-82. [PMID: 22106227 DOI: 10.1128/AAC.00370-11] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
75 Archary M, Mcllleron H, Bobat R, LaRussa P, Sibaya T, Wiesner L, Hennig S. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes. Br J Clin Pharmacol 2019;85:2066-75. [PMID: 31141195 DOI: 10.1111/bcp.13998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
76 Ren Y, Guo Y, Feng L, Li T, Du Y. Controversy and Strategies Exploration in Blocking Mother-to-Child Transmission of Hepatitis B. Int Rev Immunol 2016;35:249-59. [PMID: 27119534 DOI: 10.3109/08830185.2015.1096934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Holdich T, Shiveley LA, Sawyer J. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007;51:2943-7. [PMID: 17242147 DOI: 10.1128/AAC.01013-06] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
78 Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011;25:279-90. [DOI: 10.1097/qad.0b013e328340feb0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
79 Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother 2012;56:3011-9. [PMID: 22391541 DOI: 10.1128/AAC.06337-11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
80 Tran TT. Hepatitis B: Treatment to prevent perinatal transmission. Clin Obstet Gynecol 2012;55:541-9. [PMID: 22510637 DOI: 10.1097/GRF.0b013e318251097a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
81 Loreno M, Bo P, Senzolo M, Cillo U, Naoumov N, Burra P. Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. Transpl Int. 2005;17:730-734. [PMID: 15717218 DOI: 10.1007/s00147-004-0785-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
82 Ye M, Wang L, Fu Q, Zhu Z, Li P, Li T. Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients. HIV Clin Trials 2010;11:230-7. [PMID: 20974578 DOI: 10.1310/hct1104-230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
83 Komorizono Y, Uchida Y, Sako K, Mawatari S, Yamaguchi H, Uomizu K. Successful Treatment by Lamivudine and Regular Hemodialysis in a Patient With Decompensated Hepatitis B Virus-Related Cirrhosis Complicated by Terminal Renal Impairment: . Journal of Clinical Gastroenterology 2004;38:831-2. [DOI: 10.1097/01.mcg.0000139055.97672.d0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Witika BA, Smith VJ, Walker RB. Top-Down Synthesis of a Lamivudine-Zidovudine Nano Co-Crystal. Crystals 2021;11:33. [DOI: 10.3390/cryst11010033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
85 Quan DJ, Peters MG. Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis. 2004;8:371-385. [PMID: 15481345 DOI: 10.1016/j.cld.2004.02.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
86 Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis. 2010;14:495-504. [PMID: 20638027 DOI: 10.1016/j.cld.2010.05.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
87 Duwal S, von Kleist M. Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1. Eur J Pharm Sci 2016;94:72-83. [PMID: 26796142 DOI: 10.1016/j.ejps.2016.01.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
88 Farrell G. Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000;61:374-9. [DOI: 10.1002/1096-9071(200007)61:3<374::aid-jmv16>3.0.co;2-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
89 Zheng J, Balsitis S, Santos R, Smith BJ, Subramanian R. Characterization of Seasonal Pharmacokinetic Variability in Woodchucks. Drug Metab Dispos 2020;48:1199-209. [PMID: 32892154 DOI: 10.1124/dmd.120.000140] [Reference Citation Analysis]
90 Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2011;16. [PMID: 21744310 DOI: 10.1007/s12072-011-9295-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
91 Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, Ruan B. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 2012;9:185. [PMID: 22947333 DOI: 10.1186/1743-422X-9-185] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
92 Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol. 2002;24:173-181. [PMID: 11856618 DOI: 10.1016/s1386-6532(01)00245-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
93 Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks CB. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002;46:2387-92. [PMID: 12121909 DOI: 10.1128/AAC.46.8.2387-2392.2002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
94 Moore KHP, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Bartlett JA. Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials. Antimicrob Agents Chemother 1999;43:3025-9. [DOI: 10.1128/aac.43.12.3025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
95 Achenbach CJ, Scarsi KK, Murphy RL. Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. Adv Ther 2010;27:1-16. [PMID: 20204580 DOI: 10.1007/s12325-010-0006-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
96 Divi RL, Doerge DR, Twaddle NC, Shockley ME, St Claire MC, Harbaugh JW, Harbaugh SW, Poirier MC. Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. Toxicol Appl Pharmacol 2008;226:206-11. [PMID: 17949768 DOI: 10.1016/j.taap.2007.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
97 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
98 Sabo JP, Lamson MJ, Leitz G, Yong CL, MacGregor TR. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci 2000;2:E1. [PMID: 11741217 DOI: 10.1208/ps020101] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
99 Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba AD, Court MH. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 2009;49:1079-90. [PMID: 19628728 DOI: 10.1177/0091270009338482] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
100 Stornaiuolo G, Stanzione M, Brancaccio G, Cuomo G, Precone V, Di Biase S, Felaco FM, Piccinino F, Gaeta GB. Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B. World J Gastroenterol 2007; 13(42): 5642-5647 [PMID: 17948940 DOI: 10.3748/wjg.v13.i42.5642] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res 2006;71:322-34. [PMID: 16716415 DOI: 10.1016/j.antiviral.2006.03.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
102 Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004; 10(6): 910-912 [PMID: 15040044 DOI: 10.3748/wjg.v10.i6.910] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
103 Olaniyan LW, Maduagwu EN, Akintunde OW, Oluwayelu OO, Brai BI. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci 2015;3:545-50. [PMID: 27275285 DOI: 10.3889/oamjms.2015.110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 van der Laan LE, Garcia-Prats AJ, Schaaf HS, Winckler JL, Draper H, Norman J, Wiesner L, McIlleron H, Denti P, Hesseling AC. Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Front Pharmacol 2021;12:722204. [PMID: 34690765 DOI: 10.3389/fphar.2021.722204] [Reference Citation Analysis]
105 Takubo T, Kato T, Kinami J, Hanada K, Ogata H. Uptake of lamivudine by rat renal brush border membrane vesicles. Journal of Pharmacy and Pharmacology 2002;54:111-7. [DOI: 10.1211/0022357021771814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
106 Lemberg DA, Palasanthiran P, Goode M, Ziegler JB. Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf 2002;25:973-91. [PMID: 12408730 DOI: 10.2165/00002018-200225140-00001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
107 Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KHP, Mudd PN, Pakes GE. Pharmacokinetics of Zidovudine and Lamivudine in Neonates following Coadministration of Oral Doses Every 12 Hours. The Journal of Clinical Pharmacology 2001;41:732-41. [DOI: 10.1177/00912700122010636] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
108 Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000;61:367-73. [DOI: 10.1002/1096-9071(200007)61:3<367::aid-jmv15>3.0.co;2-a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
109 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(7): 1678-1681 [DOI: 10.11569/wcjd.v12.i7.1678] [Reference Citation Analysis]
110 Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food. JAIDS Journal of Acquired Immune Deficiency Syndromes 2014;66:393-8. [DOI: 10.1097/qai.0000000000000193] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
111 Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opinion on Drug Metabolism & Toxicology 2009;6:105-14. [DOI: 10.1517/17425250903490418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
112 Ngumba E, Gachanja A, Tuhkanen T. Occurrence of selected antibiotics and antiretroviral drugs in Nairobi River Basin, Kenya. Science of The Total Environment 2016;539:206-13. [DOI: 10.1016/j.scitotenv.2015.08.139] [Cited by in Crossref: 98] [Cited by in F6Publishing: 75] [Article Influence: 16.3] [Reference Citation Analysis]
113 Sneha R, Vedha Hari B, Ramya Devi D. Design of antiretroviral drug-polymeric nanoparticles laden buccal films for chronic HIV therapy in paediatrics. Colloid and Interface Science Communications 2018;27:49-59. [DOI: 10.1016/j.colcom.2018.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
114 Ramesh D, Vijayakumar BG, Kannan T. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections. ChemMedChem 2021;16:1403-19. [PMID: 33427377 DOI: 10.1002/cmdc.202000849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
115 Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir Ther 2010;15:297-305. [PMID: 20516550 DOI: 10.3851/IMP1532] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
116 Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother 2012;56:1427-33. [PMID: 22183172 DOI: 10.1128/AAC.05599-11] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
117 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004;40:719-726. [PMID: 15349912 DOI: 10.1002/hep.20374] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
119 Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC;  HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-138. [PMID: 25234519 DOI: 10.1093/cid/ciu617] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 21.6] [Reference Citation Analysis]
120 Jordan HL, Pereira AS, Cohen MS, Kashuba AD. Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma. Antimicrob Agents Chemother 2001;45:2173-6. [PMID: 11408248 DOI: 10.1128/AAC.45.7.2173-2176.2001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
121 Nurutdinova D, Overton ET. A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV. Expert Opin Drug Saf 2009;8:683-94. [PMID: 19715450 DOI: 10.1517/14740330903241584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
122 Phillips AN, Youle MS, Lampe F, Johnson M, Sabin CA, Lepri AC, Loveday C. Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection: . AIDS 2003;17:1009-16. [DOI: 10.1097/00002030-200305020-00009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
123 Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585. [PMID: 15889353 DOI: 10.1086/430257] [Cited by in Crossref: 399] [Cited by in F6Publishing: 350] [Article Influence: 23.5] [Reference Citation Analysis]
124 Jungmann NA, Lang D, Saleh S, Van Der Mey D, Gerisch M. In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat. Expert Opin Drug Metab Toxicol 2019;15:975-84. [PMID: 31619082 DOI: 10.1080/17425255.2019.1681968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37 Suppl 1:S2-S12. [PMID: 15319664 DOI: 10.1097/01.qai.0000137001.40505.56] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.2] [Reference Citation Analysis]
126 Dooghaie Moghadam A, Eslami P, Dowlati Beirami A, Iravani S, Farokhi E, Mansour-Ghanaei A, Hashemi MR, Aghajanpoor Pasha M, Mehrvar A, Nassiri-Toosi M. An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation. Middle East J Dig Dis 2021;13:5-14. [PMID: 34712432 DOI: 10.34172/mejdd.2021.197] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Schiff ER. Lamivudine for hepatitis B in clinical practice. J Med Virol 2000;61:386-91. [DOI: 10.1002/1096-9071(200007)61:3<386::aid-jmv18>3.0.co;2-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
128 Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trépo C. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology. 2000;32:1078-1088. [PMID: 11050059 DOI: 10.1053/jhep.2000.19619] [Cited by in Crossref: 149] [Cited by in F6Publishing: 146] [Article Influence: 6.8] [Reference Citation Analysis]
129 Wonganan P, Limpanasithikul W, Jianmongkol S, Kerr SJ, Ruxrungtham K. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection. Expert Opin Drug Metab Toxicol 2020;16:551-64. [PMID: 32508203 DOI: 10.1080/17425255.2020.1772755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Jarvis B, Perry CM. Management of Chronic Hepatitis B: Defining the Role of Lamivudine. Disease Management and Health Outcomes 2001;9:215-34. [DOI: 10.2165/00115677-200109040-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
131 Ghazi Suliman MA, Ogungbenro K, Kosmidis C, Ashworth A, Barker J, Szabo-Barnes A, Davies A, Feddy L, Fedor I, Hayes T, Stirling S, Malagon I. The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine. J Crit Care 2017;40:113-8. [PMID: 28384599 DOI: 10.1016/j.jcrc.2017.03.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
132 Wood BR, Pozniak AL. Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance! AIDS 2021;35:1305-7. [PMID: 34076616 DOI: 10.1097/QAD.0000000000002903] [Reference Citation Analysis]
133 Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R; IMPAACT P1056 Team. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J 2010;29:940-4. [PMID: 20453709 DOI: 10.1097/INF.0b013e3181e2189d] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
134 Loreno M, Bo P, Senzolo M, Cillo U, Naoumov N, Burra P. Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. Transplant Int 2004;17:730-4. [DOI: 10.1111/j.1432-2277.2004.tb00502.x] [Reference Citation Analysis]
135 Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, Kuritzkes D. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 2018;78:125-35. [PMID: 29474268 DOI: 10.1097/QAI.0000000000001660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 11.3] [Reference Citation Analysis]
136 Piana C, Danhof M, Della Pasqua O. Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV. Expert Opin Drug Metab Toxicol 2017;13:497-511. [PMID: 28043170 DOI: 10.1080/17425255.2017.1277203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
137 Ribeiro RMP, Moreira FL, Moisés ECD, Cavalli RC, Quintana SM, Lanchote VL, Duarte G. Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women. Br J Clin Pharmacol 2018;84:2415-21. [PMID: 29959798 DOI: 10.1111/bcp.13700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
138 Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003;44:759-66. [PMID: 12802911 DOI: 10.1080/104281903100006351] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
139 Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006;50:2309-15. [PMID: 16801406 DOI: 10.1128/AAC.01313-05] [Cited by in Crossref: 31] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
140 Mathayan M, Jayaraman S, Kulanthaivel L, Suresh A. Inhibition studies of HBV DNA polymerase using seed extracts of Pongamia pinnata. Bioinformation 2019;15:506-12. [PMID: 31485136 DOI: 10.6026/97320630015506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37:1132-1156. [PMID: 23638982 DOI: 10.1111/apt.12324] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 12.0] [Reference Citation Analysis]
142 Halling Folkmar Andersen A, Tolstrup M. The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection. Viruses 2020;12:E412. [PMID: 32272815 DOI: 10.3390/v12040412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Abduljalil K, Pansari A, Ning J, Jamei M. Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach. Clin Pharmacokinet. [DOI: 10.1007/s40262-021-01103-0] [Reference Citation Analysis]
144 Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006;21:657-63. [PMID: 16677149 DOI: 10.1111/j.1440-1746.2006.04082.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
145 Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O. Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol 2014;77:861-72. [PMID: 24118070 DOI: 10.1111/bcp.12247] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
146 Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol 2012;52:1824-32. [PMID: 22180560 DOI: 10.1177/0091270011426563] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
147 Balestrieri E, Forte G, Matteucci C, Mastino A, Macchi B. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother 2002;46:3080-3. [PMID: 12183277 DOI: 10.1128/AAC.46.9.3080-3083.2002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
148 Galato D, Schuelter-Trevisol F, Piovezan AP. Measurement complexity of adherence to medication. Ther Clin Risk Manag 2012;8:169-71. [PMID: 22547935 DOI: 10.2147/TCRM.S30849] [Reference Citation Analysis]
149 Abhyankar D, Shedage A, Gole M, Raut P. Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study. Int J STD AIDS 2017;28:491-8. [DOI: 10.1177/0956462416655955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Schreij G, Janknegt R. InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'. Expert Opin Pharmacother 2007;8 Suppl 1:S37-47. [PMID: 17931077 DOI: 10.1517/14656566.8.s1.s37] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
151 Bouazza N, Tréluyer JM, Ghosn J, Hirt D, Benaboud S, Foissac F, Viard JP, Urien S. Evaluation of effect of impaired renal function on lamivudine pharmacokinetics. Br J Clin Pharmacol 2014;78:847-54. [PMID: 24750102 DOI: 10.1111/bcp.12407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
152 Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger T, Vangerow H, Hayward K, Shaefer M, McCoig C. Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study. Clin Pharmacol Ther 2018;103:402-8. [PMID: 29150845 DOI: 10.1002/cpt.943] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
153 Jiang J, Hu P, Xie H, Chen H, Fan F, Harker A, Johnson MA. The pharmacokinetics of lamivudine in healthy Chinese subjects. Br J Clin Pharmacol 1999;48:250-3. [PMID: 10417505 DOI: 10.1046/j.1365-2125.1999.00984.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
154 Babayeva M, Cox S, White MP, Taft DR. Renal excretion of apricitabine in rats: ex vivo and in vivo studies. Eur J Drug Metab Pharmacokinet 2011;36:141-50. [PMID: 21744041 DOI: 10.1007/s13318-011-0038-9] [Reference Citation Analysis]
155 Hughes DA, Aronson JK. A systematic review and empirical analysis of the relation between dose and duration of drug action. J Clin Pharmacol 2010;50:17-26. [PMID: 19797537 DOI: 10.1177/0091270008329555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
156 Mdanda S, Ntshangase S, Singh SD, Naicker T, Kruger HG, Baijnath S, Govender T. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay Drug Dev Technol 2019;17:322-9. [PMID: 31634020 DOI: 10.1089/adt.2019.941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Wolters LM, Hansen BE, Niesters HG, Levi-drummer RS, Neumann AU, Schalm SW, de Man RA. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. Journal of Hepatology 2002;37:253-8. [DOI: 10.1016/s0168-8278(02)00113-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
158 Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis. 2007;11:945-963, x. [PMID: 17981236 DOI: 10.1016/j.cld.2007.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
159 Bruno R, Regazzi MB, Ciappina V, Villani P, Sacchi P, Montagna M, Panebianco R, Filice G. Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIV: . Clinical Pharmacokinetics 2001;40:695-700. [DOI: 10.2165/00003088-200140090-00005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
160 Mounzer K, Brunet L, Wyatt CM, Fusco JS, Vannappagari V, Tenorio AR, Shaefer MS, Ragone L, Hsu RK, Fusco GP. To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. AIDS 2021;35:1201-8. [PMID: 33710017 DOI: 10.1097/QAD.0000000000002871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, Rowland L, MacGregor TR, Castles MA, Robinson P. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther 2012;37:81-8. [PMID: 21128991 DOI: 10.1111/j.1365-2710.2010.01235.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
162 Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. Am J Addict 2010;19:17-29. [PMID: 20132118 DOI: 10.1111/j.1521-0391.2009.00004.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
163 Park GJ, Katelaris PH, Jones DB, Seow F, Lin BPC, Le Couteur DG, Ngu MC. The 13C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005;22:395-403. [DOI: 10.1111/j.1365-2036.2005.02623.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
164 Asari A, Iles-Smith H, Chen YC, Naderer OJ, Johnson MA, Yuen GJ, Otto V, Dunn JA, Gokal R. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br J Clin Pharmacol 2007;64:738-44. [PMID: 17662093 DOI: 10.1111/j.1365-2125.2007.02963.x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
165 Keating MR. Antiviral Agents for Non-Human Immunodeficiency Virus Infections. Mayo Clinic Proceedings 1999;74:1266-83. [DOI: 10.4065/74.12.1266] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
166 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107. [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 1509] [Article Influence: 91.4] [Reference Citation Analysis]
167 Takubo T, Kato T, Kinami J, Hanada K, Ogata H. Effect of Lamivudine on Uptake of Organic Cations by Rat Renal Brush-Border and Basolateral Membrane Vesicles. Journal of Pharmacy and Pharmacology 2000;52:569-75. [DOI: 10.1211/0022357001774219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
168 De Sousa Mendes M, Chetty M. Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs R D 2019;19:339-50. [PMID: 31602556 DOI: 10.1007/s40268-019-00285-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
169 Heller S, Valencia-mayoral P. Treatment of Viral Hepatitis in Children. Archives of Medical Research 2007;38:702-10. [DOI: 10.1016/j.arcmed.2006.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
170 Fok BS, Gardner S, Piscitelli S, Chen S, Chu TT, Chan JC, Tomlinson B. Pharmacokinetic Properties of Single-Dose Lamivudine/Adefovir Dipivoxil Fixed-Dose Combination in Healthy Chinese Male Volunteers. Clinical Therapeutics 2013;35:68-76. [DOI: 10.1016/j.clinthera.2012.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:147-159. [PMID: 20567182 DOI: 10.1097/aog.0b013e3181e45951] [Cited by in Crossref: 120] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
172 Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Review of Gastroenterology & Hepatology 2014;5:323-39. [DOI: 10.1586/egh.11.7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
173 Zhang YT, Liu J, Pan XB, Gao YD, Hu YF, Lin L, Cheng HJ, Chen GY. Successful treatment of infantile hepatitis B with lamivudine: A case report. World J Clin Cases 2021; 9(14): 3442-3448 [PMID: 34002156 DOI: 10.12998/wjcc.v9.i14.3442] [Reference Citation Analysis]
174 Ceckova M, Reznicek J, Deutsch B, Fromm MF, Staud F. Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate). PLoS One 2018;13:e0202706. [PMID: 30114293 DOI: 10.1371/journal.pone.0202706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
175 Zhang C, Denti P, van der Walt J, Ren Y, Smith P, Karlsson MO, Mcilleron H. Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring. Therapeutic Drug Monitoring 2012;34:481-4. [DOI: 10.1097/ftd.0b013e31825c6067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
176 Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011;86:1009-26. [PMID: 21964179 DOI: 10.4065/mcp.2011.0309] [Cited by in Crossref: 137] [Cited by in F6Publishing: 106] [Article Influence: 12.5] [Reference Citation Analysis]
177 Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol. 2002;17 Suppl:S125-S145. [PMID: 12000599 DOI: 10.1046/j.1440-1746.17.s1.3.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
178 Fischetti B, Shah K, Taft DR, Berkowitz L, Bakshi A, Cha A. Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment. Open Forum Infect Dis 2018;5:ofy225. [PMID: 30302352 DOI: 10.1093/ofid/ofy225] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
179 García-Trejo JJ, Ortega R, Zarco-Zavala M. Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients. Front Oncol 2021;11:664794. [PMID: 34367956 DOI: 10.3389/fonc.2021.664794] [Reference Citation Analysis]